Patients with NK/T‐cell lymphoma, another type of EBV‐associated disease, could probably also benefit from treatments with BCL‐2 inhibitors, as high expression of BCL‐2 in the tumor cells has been shown to be associated with a poor prognosis [38]. This evidence concerns the gene BCL2 and neoplasm.